13th Oct 2006 12:00
THIRD QUARTER 2006 RESULTS DATE NOTIFICATION - October 27, 2006Basingstoke, UK and Philadelphia, US - October 13, 2006 - Shire plc (LSE: SHP,NASDAQ: SHPGY, TSX: SHQ) will announce third quarter 2006 US GAAP earnings onFriday, October 27, 2006.Results announcement time: 12:00 BST / 07:00 ET Conference call time: 14:00 BST / 09:00 ET Live analyst conference call:Matthew Emmens, Chief Executive Officer, Angus Russell, Chief Financial Officerand David Pendergast, President, Human Genetic Therapies will host the liveanalyst conference call at 14:00 BST/09:00 ET.Please RSVP [email protected] (T: +44 (0)1256 894 160).The details of the live conference call are as follows:Canada Toll Free Dial In Number 1800 795 6202 US Toll Free Dial In Number 1866 224 2914 UK Toll Free Dial In Number 0800 953 0937 Standard International Dial In + 44 (0)1452 569 103 Number Conference ID 8001751 Live Webcast:The call will also be available live over the Internet via audio webcast,accessible through www.shire.com in the Investor Relations/Events section. Aslide presentation to accompany the call will also be available in the samesection.Replay:A replay of the presentation will be available for two weeks. Details are asfollows:UK Dial In Number 0800 953 1533 USA Toll Free Number 1866 247 4222 Std International Number +44 (0) 1452 55 00 00 Replay Access Number 8001751 # Webcast Replay www.shire.com, in the Investor Relations/Events section For further information please contact:Investor Relations Souheil Salah (Rest of the World) +44 1256 894 160 Heidi Wunder (North America) +1 484 595 8709 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 5492592 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire